5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
Complete regulatory overview of suvorexant (Belsomra) across the US, EU, Canada, and UK, including FDA approval history, EMA status, mechanism of action, and prescribing classifications.
Evidence-based guide to suvorexant (Belsomra) storage conditions, chemical stability, shelf life, and proper handling based on FDA labeling and pharmaceutical stability data.
A physician-level review of every clinically significant drug-drug interaction for suvorexant (Belsomra), covering CYP3A4 inhibitors and inducers, CNS depressants, opioids, alcohol, and orexin-pathway considerations with PubMed and FDA evidence.
A guide to discontinuing suvorexant (Belsomra), covering tapering schedules, rebound insomnia risk, mechanism of action, and when to seek medical help.
Belsomra's FDA label warns about use in compromised respiratory function, plus next-day impairment, complex sleep behaviors, and no boxed warning.